Table of Contents
Invitation to invest in pharmaceuticals ........................................... 8
Bottom-line projections: EPS...................................................... 12
Estimating gross margins............................................................ 13
Understanding licensing ............................................................. 14
M&A.............................................................................................. 16
Frequently used terms: M&A-related......................................... 18
Individual companies ...................................................................... 20
Takeda Pharmaceutical (4502) .................................................... 22
Astellas Pharma (4503) ................................................................ 24
Shionogi (4507) ............................................................................ 26
Mitsubishi Tanabe Pharma (4508) .............................................. 28
Chugai Pharmaceutical (4519)..................................................... 30
Eisai (4523).................................................................................... 32
Ono Pharmaceutical (4528) ......................................................... 34
Daiichi Sankyo (4568) .................................................................. 36
Taisho Pharmaceutical (4535) ..................................................... 38
Kissei Pharmaceutical (4547) ...................................................... 40
Pharmaceutical industry outlook ................................................... 42
Domestic sales: top 50 drugs...................................................... 52
MR numbers: the top 30 companies .......................................... 54
MR productivity ........................................................................... 55
Prescription drug approval process ........................................... 56
Responsible government authorities ......................................... 57
The drug price system................................................................. 58
Drugs and drug costs................................................................... 60
Drug price revisions..................................................................... 62
NHI drug price revisions and the prescription drug market .... 63
NHI drug price revisions in ‘08.................................................... 64
Outlook for NHI drug price revisions in 2010 ............................ 65
Generic drugs ............................................................................... 66
OTC drugs..................................................................................... 68
Kampo (Chinese herbal medicine).............................................. 72
The US market ................................................................................. 77
The US market (1): US healthcare reform ..................................... 78
The US market (2): Medicare ...................................................... 79
The US market (3): Japanese firms’ products ........................... 80
The US market (4): Patents ......................................................... 81
The US market (5): Generics ....................................................... 84
The US market (6): IMS data....................................................... 85
Understanding pharmaceuticals: Vocabulary............................. 103
Pharmaceutical nomenclature .................................................. 104
Agonists and antagonists.......................................................... 105
Molecular-targeted treatments .................................................. 106
RNAi and Aptamers ................................................................... 108
AIDS (Acquired Immunodeficiency Syndrome) ...................... 110
Vaccines...................................................................................... 112
RA treatments: Biologics........................................................... 114
Proton pump inhibitors (PPI) .................................................... 115
Alzheimer’s drugs ...................................................................... 116
Osteoporosis .............................................................................. 118
Angiotensin II receptor blockers (ARB).................................... 120
Anti-diabetic drugs .................................................................... 122
Glitazone drugs (TZD)................................................................ 124
Gliptin drugs............................................................................... 125
Hyperlipidemia treatments ....................................................... 126
Arterial thrombosis.................................................................... 128
Venous thrombosis.................................................................... 130
Glycoengineering....................................................................... 132
Influenza ..................................................................................... 134
Frequently used terms .................................................................. 137
Frequently used terms: Clinical trials....................................... 138
Frequently used terms: Clinical trials (continuation 1)........... 140
Frequently used terms (continuation 2) ...................................... 142
Frequently used terms: Pharmacokinetics (PK) ...................... 144
Frequently used terms: Drugs .................................................. 146
Frequently used terms: Side effects..................................... 148
Frequently used terms: Statistics............................................. 150
Frequently used terms: Miscellaneous .................................... 152
Abbreviations and acronyms........................................................ 159
Calendar ......................................................................................... 170
In closing ........................................................................................ 171
About the Authors ..................................................................... 172
Staying healthy .......................................................................... 174